Modern approaches to the therapy of invasive mycoses in cancer patients
- Authors: Prikhodchenko A.O.1, Nechuskina V.M.1, Vyatkin P.V.1
-
Affiliations:
- Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
- Issue: Vol 23, No 2 (2021)
- Pages: 349-353
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/77946
- DOI: https://doi.org/10.26442/18151434.2021.2.200708
- ID: 77946
Cite item
Full Text
Abstract
There is an increase in the prevalence of Candida fluco-R, there is a transition from strains of C. albicans to C. non-albicans. Diagnosis of invasive fungal infections is based on a clinical picture and risk factor assessment with subsequent retrospective confirmation of the diagnosis by a microbiological method. Echinocandines are the drugs of choice in the therapy of invasive/systemic mycoses in cancer patients.
Full Text
##article.viewOnOriginalSite##About the authors
Aleksey O. Prikhodchenko
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Author for correspondence.
Email: evpatii2004@mail.ru
ORCID iD: 0000-0002-4770-0034
Cand. Sci. (Med.)
Russian Federation, MoscowValentina M. Nechuskina
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: evpatii2004@mail.ru
ORCID iD: 0000-0002-1855-9692
D. Sci. (Med.)
Russian Federation, MoscowPavel V. Vyatkin
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: evpatii2004@mail.ru
ORCID iD: 0000-0003-2976-2562
anesthesiologist-resuscitator
Russian Federation, MoscowReferences
- Веселов А.В. Эмпирическая терапия инвазивного кандидоза в отделениях реанимации и интенсивной терапии: современное состояние проблемы. Клиническая микробиология и антимикробная химиотерапия. 2011;13(1):4-18 [Veselov AV. Empiricheskaia terapiia invazivnogo kandidoza v otdeleniiakh reanimatsii i intensivnoi terapii: sovremennoe sostoianie problemy. Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia. 2011;13(1):4-18 (in Russian)].
- Нехаев И.В., Приходченко А.О., Ломидзе С.В., Сытов А.В. Интенсивная терапия системных микозов в онкохирургии. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2014;25(1–2):52-8 [Nekhaev IV, Prikhodchenko AO, Lomidze SV, Sytov AV. Intensivnaia terapiia sistemnykh mikozov v onkokhirurgii. Vestnik RONTs im. N.N. Blokhina RAMN. 2014;25(1–2):52-8 (in Russian)].
- Нехаев И.В., Приходченко А.О., Ломидзе С.В., Сытов А.В. Диагностика и лечение системных микозов в онкохирургии. Инфекции в хирургии. 2014;2:17-21 [Nekhaev IV, Prikhodchenko AO, Lomidze SV, Sytov AV. Diagnostika i lechenie sistemnykh mikozov v onkokhirurgii. Infektsii v khirurgii. 2014;2:17-21 (in Russian)].
- Нехаев И.В., Приходченко А.О., Бударгин Е.Е., и др. Флуконазол. Эхинокандины. Системные микозы. Медицинский алфавит. 2015;3(14):23-9 [Nekhaev IV, Prikhodchenko AO, Budargin EE, et al. Flukonazol. Ekhinokandiny. Sistemnye mikozy. Meditsinskii alfavit. 2015;3(14):23-9 (in Russian)].
- Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-5.
- Voss A, le Noble JL, Verduyn Lunel FM, et al. Candidemia in intensive care unit patients: risk factors for mortality. Infection. 1997;25:8-11.
- Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med. 2002;113:480-5.
- Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-17.
- Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-7.
- Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-9.
- Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-5.
- Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
- Vincent JL, Rello J, Marshall J, et al. EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323-9.
- Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606-18.
- Tortorano AM, Kibbler C, Peman J, et al. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents. 2006;27:359-66.
- Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med. 2009;35:55-62.
- Muñoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents. 2000;15:83-90.
- Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003;17:113-34.
- Pelz RK, Lipsett PA, Swoboda SM, et al. The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect (Larchmt). 2000;1:273-81.
- Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142-51.
- Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother. 2010;65(6):1108-18.
- Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol. 2010;48(1):52-6.
- Kale-Pradhan PB, Morgan G, Wilhelm SM, Johnson LB. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis. Pharmacotherapy. 2010;30:1207-13.
- Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents. 2010;35:211-18.
- Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10:121-30.
- Cota J, Carden M, Graybill JR, et al. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother. 2006;50(11):3926-8.
- Edlind T, Healey K, Jphnson M, Katiyar S. Candida glabrata CRS-MIS Mutants: Caspofungin Reduced Susceptibility but Micafungin Increased Susceptibility. 2010. Poster M-393; 50th ICAAC, Boston, MA, USA.
- Niwa T, Yokota Y, Tokunaga A, et al. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull. 2004;27:1154-6.
- Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743, 872). Antimicrob Agents Chemother. 1997;41:2339-44.
- Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother. 2008;52:2673-6.
- Damle BD, Dowell JA, Walsky RL, et al. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother. 2009;53:1149-56.
- Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;3:71-97.
- Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36:1445-57.
- Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006;42:1171-8.
- Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43:215-22.
- Krause DS, Reinhardt J, Vazquez JA, et al. Anidulafungin Invasive Candidiasis Study Group. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021-4.
- Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44:590-8.
- Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47:461-70.
- European Medicines Agency. Ecalta® summary of product characteristics. 2010.
- Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol. 2005;45:227-33.
- Dowell JA, Stogniew M, Krause D, et al. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol. 2007;47:305-14.
- Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol. 2005;45:1373-82.
- Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother. 2004;48:4306-14.
- Betts RF, Nucci M, Talwar D, et al. Caspofungin High-Dose Study Group A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676-84.
- Mistry GC, Migoya E, Deutsch PJ, et al. Single-and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol. 2007;47:951-61.
- European Medicines Agency. Cancidas® summary of product characteristics. 2009. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cancidas-previously-caspofungin-msd. Accessed: 24.08.2020.
- European Medicines Agency. Mycamine® summary of product characteristics. 2010. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine. Accessed: 25.08.2020.
- Sandven P, Bevanger L, Digranes A, et al. Norwegian Yeast Study Group Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. 2006;44:1977-81.
- Slavin MA, Sorrell TC, Marriott D, et al. Australian Candidemia Study, Australasian Society for Infectious Diseases: Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother. 2010;65:1042-51.
- Kumar A, Skrobik I, Guzman J, et al. CATSS Database Research Group. The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. Poster K-2174; 47th ICAAC, Chicago, IL, USA, 2007.
- Taur Y, Cohen N, Dubnow S, et al. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010;54:184-90.
- European Medicines Agency. Diflucan® summary of product characteristics. 2010. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/diflucan. Accessed: 24.08.2020.
- Nivoix Y, Ubeaud-Sequier G, Engel P, et al. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab. 2009;10(4):395-409.
- Kullberg BJ, Vasquez J, Mootsikapun P. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. J Antimicrob Chemother. 2017;72(8):2368-77. doi: 10.1093/jac/dkx116